BioGX: Difference between revisions
Jump to navigation
Jump to search
(Created page with "'''BioGX''' is a molecular diagnostics company with offices in Birmingham's Innovation Depot. The company also operates a second manufacturing and distribution center,...") |
No edit summary |
||
| Line 3: | Line 3: | ||
BioGX was founded in [[2007]] by [[Michael Vickery]]. [[Shazi Iqbal]] has served as CEO since [[2011]]. Both are veterans of the Sunnyvale, California-based Cepheid Inc. | BioGX was founded in [[2007]] by [[Michael Vickery]]. [[Shazi Iqbal]] has served as CEO since [[2011]]. Both are veterans of the Sunnyvale, California-based Cepheid Inc. | ||
BioGX partnered with Becton Dickinson & Co. of New Jersey to develop a rapid [[2020 Coronavirus pandemic|COVID-19]] RNA test for its "BD Max" diagnostic platform. The test was granted an emergency use authorization from the U.S. Food and Drug Administration in April 2020. | BioGX partnered with Becton Dickinson & Co. of New Jersey to develop a rapid [[2020 Coronavirus pandemic|COVID-19]] RNA test for its "BD Max" diagnostic platform. The test was granted an emergency use authorization from the U.S. Food and Drug Administration in April 2020. It's "XFree" test process was given the same type of approval in October. | ||
==References== | ==References== | ||
* Patchen, Tyler (March 17, 2020) "Birmingham biotech firm collaborating on COVID-19 diagnostics." {{BBJ}} | * Patchen, Tyler (March 17, 2020) "Birmingham biotech firm collaborating on COVID-19 diagnostics." {{BBJ}} | ||
* Patchen, Tyler (April 6, 2020) "Bham biotech firm's COVID-19 test collaboration gets FDA authorization." {{BBJ}} | * Patchen, Tyler (April 6, 2020) "Bham biotech firm's COVID-19 test collaboration gets FDA authorization." {{BBJ}} | ||
* Patchen, Tyler (October 27, 2020) "Birmingham company secures FDA emergency use authorization for Covid-19 test." {{BBJ}} | |||
==External links== | ==External links== | ||
Revision as of 16:58, 27 October 2020
BioGX is a molecular diagnostics company with offices in Birmingham's Innovation Depot. The company also operates a second manufacturing and distribution center, BioGX BV, in Amsterdam, the Netherlands.
BioGX was founded in 2007 by Michael Vickery. Shazi Iqbal has served as CEO since 2011. Both are veterans of the Sunnyvale, California-based Cepheid Inc.
BioGX partnered with Becton Dickinson & Co. of New Jersey to develop a rapid COVID-19 RNA test for its "BD Max" diagnostic platform. The test was granted an emergency use authorization from the U.S. Food and Drug Administration in April 2020. It's "XFree" test process was given the same type of approval in October.
References
- Patchen, Tyler (March 17, 2020) "Birmingham biotech firm collaborating on COVID-19 diagnostics." Birmingham Business Journal
- Patchen, Tyler (April 6, 2020) "Bham biotech firm's COVID-19 test collaboration gets FDA authorization." Birmingham Business Journal
- Patchen, Tyler (October 27, 2020) "Birmingham company secures FDA emergency use authorization for Covid-19 test." Birmingham Business Journal
External links
- BioGX website